Report for Q1 2026
Filed with SSE · · 18 pages · Chinese
Kangmei Pharmaceutical Co., Ltd on 6ix
Earlier from Kangmei Pharmaceutical
- Announcement on Resignation of Director
- Announcement on Not Planning Profit Distribution for 2025
- Announcement on Transfer of Equity and Related Assets of the Wholly-owned Subsidiary
- Announcement on Supplementary Payment of Taxes by the Wholly-owned Subsidiary
- Announcement on Change of Signatory Certified Public Accountant and Project Quality Control Review Partner
Later from Kangmei Pharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Changing Business Scope and Amending the Articles of Association
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Progress in Litigation Involved
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
Follow Kangmei Pharmaceutical into a list and get an email when it puts out news.
Follow Kangmei Pharmaceutical